Swissmedic approves IFINWIL for children with high-risk neuroblastoma
Swissmedic approved the registration of IFINWIL (eflornithine) as a monotherapy to treat paediatric patients with high-risk neuroblastoma,
Swissmedic approved the registration of IFINWIL (eflornithine) as a monotherapy to treat paediatric patients with high-risk neuroblastoma,
What's Your Reaction?
